AR005278A1 - Derivados de 1- (piperidinil 1,2 - disustituido) -4- (imidazol fusionado) -piperidina, proceso para la preparación de los mismos, composición farmacéutica que los contiene y proceso para la preparación de dicha composición. - Google Patents

Derivados de 1- (piperidinil 1,2 - disustituido) -4- (imidazol fusionado) -piperidina, proceso para la preparación de los mismos, composición farmacéutica que los contiene y proceso para la preparación de dicha composición.

Info

Publication number
AR005278A1
AR005278A1 ARP960105895A ARP960105895A AR005278A1 AR 005278 A1 AR005278 A1 AR 005278A1 AR P960105895 A ARP960105895 A AR P960105895A AR P960105895 A ARP960105895 A AR P960105895A AR 005278 A1 AR005278 A1 AR 005278A1
Authority
AR
Argentina
Prior art keywords
formula
alkyl
radical
preparation
hydrogen
Prior art date
Application number
ARP960105895A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR005278A1 publication Critical patent/AR005278A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen derivados 1-(piperidinil 1,2-disustituido)-4- (imidazolfusionado)-piperidina, que comprende un compuesto de la fórmula (I),en forma N-óxido, una sal de adición farmacéuticamente aceptable o una forma estereoquímicamen te isomérica delmismo, donde n es 0,1o 2; m es 1 o 2, siempreque si m es 2, n sea 1; =Q es =O o =NR3; X es un enlace covalente o un radical bivalente de la fórmula -O-, -S-, NR3-; R1 es Ar1.Ar1 alquilo C1-6 o di(Ar1)alquilo C1-6, donde cada grupo a lquilo C1-C6está optaitvamentte sustituido con hidroxi, alquilox C1-C4, oxo o un sustituyente oxo cetalizado de lafórmula -O-CH2-CH2-O o -O-CH2-CH2-CH2-O-; R2 es Ar2, Ar2 alquilo C1-6, Het o Het alquilo C1-6; R3 es hidrógeno o alquilo C1-C6; L es un radicalde lafórmula (a-1) o (a2),en la cual la línea de puntos es un enlace optativo; cada -A-B es, independientemente, un radical bivalente de la fórmula: Y-CR7=CH-(b-1); -CH=CR7-Y (b-2); -CH=CH-CH=CH- (b-3); -CH=CR7-CH=CH- (b-4); -CH=CH-CR7=CH- (b-5); o-CH=CH-CH=CR7 (b-6) en el cual cada Y esindependientemente , alquilo C1-6, halo, etenilo sustituido con carboxilo o alquiloxicarbonilo C1-C6, hidroxialquilo C1-C6; o R7 es hidrógeno en el casoque -A-B- es un radical de fórmula (b-1)o (b-2); R8 eshidrógeno, alquilo C1-C6 o alquilcarbonilo C1-C6; cada Z es, independientemente, Z1 o Z2; dondeZ1 es un radical bivalente de la fórmula -CH2-, -CH2-CH2-,o -CH=Ch-, siempre que cuando L es un radical de la fórmu la (a-1) y la línea de puntos esunenlace adicional, Z1 no sea -CH2-; Z2 es un radical bivalente de la fórmula -CH2-CHOH, -CH2-O-, -CH2C(=O)- o -CH2-C(=NOH)-, siempre que la porción -CH2- dedichos radicales bivalentes esté conectada al nitrógeno del anillo de imidazol; cada R4 es,independientemente, hidrógeno, alquilo C1-C6, halo, etenilo
ARP960105895A 1995-12-27 1996-12-26 Derivados de 1- (piperidinil 1,2 - disustituido) -4- (imidazol fusionado) -piperidina, proceso para la preparación de los mismos, composición farmacéutica que los contiene y proceso para la preparación de dicha composición. AR005278A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95203652 1995-12-27

Publications (1)

Publication Number Publication Date
AR005278A1 true AR005278A1 (es) 1999-04-28

Family

ID=8221024

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960105895A AR005278A1 (es) 1995-12-27 1996-12-26 Derivados de 1- (piperidinil 1,2 - disustituido) -4- (imidazol fusionado) -piperidina, proceso para la preparación de los mismos, composición farmacéutica que los contiene y proceso para la preparación de dicha composición.
ARP050105316A AR051817A2 (es) 1995-12-27 2005-12-16 Derivados de piperidina-1-(1,2-piperidinil disustituidos)-4-(imidazol condensados)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP050105316A AR051817A2 (es) 1995-12-27 2005-12-16 Derivados de piperidina-1-(1,2-piperidinil disustituidos)-4-(imidazol condensados)

Country Status (29)

Country Link
US (1) US6251894B1 (es)
EP (1) EP0843679B1 (es)
JP (1) JP4097043B2 (es)
KR (1) KR100485147B1 (es)
CN (1) CN1066733C (es)
AR (2) AR005278A1 (es)
AT (1) ATE208392T1 (es)
AU (1) AU716071B2 (es)
BR (1) BR9612307A (es)
CA (1) CA2238817C (es)
CY (1) CY2271B1 (es)
CZ (1) CZ295861B6 (es)
DE (1) DE69616802T2 (es)
DK (1) DK0843679T3 (es)
EA (1) EA001374B1 (es)
ES (1) ES2167619T3 (es)
HU (1) HU229766B1 (es)
IL (2) IL124642A (es)
MY (1) MY117680A (es)
NO (1) NO310916B1 (es)
NZ (1) NZ325845A (es)
PL (1) PL183767B1 (es)
PT (1) PT843679E (es)
SI (1) SI0843679T1 (es)
SK (1) SK283540B6 (es)
TR (1) TR199801210T2 (es)
TW (1) TW382017B (es)
WO (1) WO1997024356A1 (es)
ZA (1) ZA9610889B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527186B (en) * 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
ATE233104T1 (de) 1997-09-18 2003-03-15 Janssen Pharmaceutica Nv Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
BR9916371A (pt) * 1998-12-19 2001-09-18 Janssen Pharmaceutica Nv Composto de espiro anti-histamìnico
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
CA2448735C (en) 2001-06-12 2008-10-28 Janssen Pharmaceutica N.V. Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
AU2002356715B2 (en) * 2001-11-23 2008-05-15 Janssen Pharmaceutica N.V. The use of anti-histaminics for acute reduction of elevated intracranial pressure
EP1457493A4 (en) * 2001-12-10 2005-11-30 Kyorin Seiyaku Kk CONDENSED, BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS
DE60300683T2 (de) * 2002-01-16 2006-04-27 Janssen Pharmaceutica N.V. Prucaloprid-n-oxid
ATE427310T1 (de) 2002-01-18 2009-04-15 Kyorin Seiyaku Kk Kondensierte bicyclische pyrimidinderivate
KR20040099367A (ko) 2002-03-26 2004-11-26 교린 세이야꾸 가부시키 가이샤 타키키닌 수용체 길항제로서의 축합 바이사이클릭 피리딘 유도체
WO2004056805A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
KR101355064B1 (ko) 2005-03-03 2014-01-24 얀센 파마슈티카 엔.브이. 치환된 옥사-디아자-스피로-[5.5]-운데카논 유도체 및뉴로키닌 길항제로서의 이의 용도
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
WO2009009829A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
ATE124045T1 (de) * 1990-10-10 1995-07-15 Schering Corp Substituierte imidazobenzazepine und imidazopyridoazepine.
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
KR100346802B1 (ko) * 1993-07-13 2002-11-29 얀센 파마슈티카 엔.브이. 항앨러지성이미다조아제핀
TW397831B (en) 1994-07-15 2000-07-11 Meiji Seika Kaisha The anti-platelet-agglutination hexahydrogenated pyridine and its derivatives
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives

Also Published As

Publication number Publication date
IL124642A0 (en) 1998-12-06
US6251894B1 (en) 2001-06-26
DE69616802D1 (de) 2001-12-13
DE69616802T2 (de) 2002-07-04
CZ186598A3 (cs) 1998-11-11
CA2238817C (en) 2006-10-17
PL183767B1 (pl) 2002-07-31
ATE208392T1 (de) 2001-11-15
CA2238817A1 (en) 1997-07-10
BR9612307A (pt) 1999-07-13
WO1997024356A1 (en) 1997-07-10
ZA9610889B (en) 1998-06-23
JP2000506503A (ja) 2000-05-30
IL124641A (en) 2001-11-25
NO982405L (no) 1998-08-19
CN1206417A (zh) 1999-01-27
DK0843679T3 (da) 2002-02-25
AR051817A2 (es) 2007-02-14
HUP9903948A3 (hu) 2000-04-28
CZ295861B6 (cs) 2005-11-16
SI0843679T1 (en) 2002-06-30
SK83098A3 (en) 1999-01-11
SK283540B6 (sk) 2003-09-11
PT843679E (pt) 2002-04-29
JP4097043B2 (ja) 2008-06-04
HUP9903948A2 (hu) 2000-03-28
CN1066733C (zh) 2001-06-06
EA199800603A1 (ru) 1998-12-24
NO982405D0 (no) 1998-05-27
EP0843679B1 (en) 2001-11-07
KR100485147B1 (ko) 2005-09-13
KR19990076715A (ko) 1999-10-15
IL124642A (en) 2002-08-14
EA001374B1 (ru) 2001-02-26
ES2167619T3 (es) 2002-05-16
HU229766B1 (hu) 2014-06-30
MY117680A (en) 2004-07-31
HK1011206A1 (en) 1999-07-09
NZ325845A (en) 1999-06-29
TR199801210T2 (xx) 1999-10-21
AU716071B2 (en) 2000-02-17
IL124641A0 (en) 1998-12-06
NO310916B1 (no) 2001-09-17
PL327136A1 (en) 1998-11-23
AU1308697A (en) 1997-07-28
EP0843679A1 (en) 1998-05-27
TW382017B (en) 2000-02-11
CY2271B1 (en) 2003-07-04

Similar Documents

Publication Publication Date Title
AR005278A1 (es) Derivados de 1- (piperidinil 1,2 - disustituido) -4- (imidazol fusionado) -piperidina, proceso para la preparación de los mismos, composición farmacéutica que los contiene y proceso para la preparación de dicha composición.
AR004698A1 (es) Derivados de piperazina 1-(piperidinil -1,2- disustituido) -4- sustituida, composicion que los contiene, proceso para preparar dicha composicion y proceso para preparar dichos derivados
US5753600A (en) Liquid detergent composition
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
KR960704852A (ko) 아졸 유도체 및 이의 약제학적 조성물 (Azole derivative and pharmaceutical composition thereof)
AR016324A1 (es) Benzamidas monociclicas de derivados 3-o-4-substituidos de 4-(aminometil)-piperidinas, procedimiento para su preparacion, compuestos intermediarios,procedimientos para la preparacion de los mismos, composicion farmaceutica y procedimiento para la preparacion de dicha composicion
AR035991A1 (es) Derivados de benzimidazoles e imidazopiridinas, un procedimiento para su preparacion, composiciones farmaceuticas, un procedimiento para su preparacion, y un medicamento utiles como inhibidores de la replicacion del virus sincitial respiratorio
AR004699A1 (es) Derivados de 2-quinolina inhibidores de la farnesil transferasa, composicion farmaceutica, proceso para preparar dicha composicion, y proceso para preparar dichos derivados.
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
BR0311345B1 (pt) composiÇço contendo resina de polipropileno cristalina, mÉtodos para prover resina de polipropileno, uso de agentes b-nucleantes, artigo conformado, filme monoaxialmente ou biaxialmente orientado, fibra e sistema de méltiplas camadas.
YU39691A (sh) Derivati n-(4-piperidinil) (dihidroben-zofuran ili dihidro-2h-benzopiran) karboksamida
HUT77318A (hu) 1-Acil-4-/(alifás amino)-piperidin/-származékok, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR037080A1 (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios
IE901799L (en) Anti inflammatory aminophenol derivatives
CO5380019A1 (es) Azalidas de 13 miembros utiles como agentes antibioticos
AR021888A1 (es) Derivados de espiro-benzazepina-piperidina, composiciones farmaceuticas que los comprenden, proceso para preparar dichas composiciones, intermediario util en la preparacion de dichos derivados, procesos para preparar dichos derivados y procesos para preparar dicho intermediario
ES2196020T3 (es) Derivados de triazolobenzazepina antialergicos.
AR005279A1 (es) Derivados 1-(piperidinil 1,2-disustituido)-4-(bencimidazolil e imidazopiridinil)-piperidina, proceso para su preparacion, composicion farmaceutica, y proceso para preparar dicha composicion
ES2191963T3 (es) Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
IL124396A (en) Substituted 4-(1h-benzimidazol-2yl-amino) piperidines and pharmaceutical compositions comprising them
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR008168A1 (es) Compuestos etilamino arilamida aril substituidos de pirrolidinilo y pirrolinilo, composicion farmaceutica que lo contiene, compuesto util para susintesis, procedimiento para su preparacion

Legal Events

Date Code Title Description
FG Grant, registration